Replimune Group, Inc. (REPL)
REPL Stock Price Chart
Explore Replimune Group, Inc. interactive price chart. Choose custom timeframes to analyze REPL price movements and trends.
REPL Company Profile
Discover essential business fundamentals and corporate details for Replimune Group, Inc. (REPL) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
20 Jul 2018
Employees
479.00
Website
https://www.replimune.comCEO
Sushil Patel
Description
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trials to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
REPL Financial Timeline
Browse a chronological timeline of Replimune Group, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 20 May 2026
Upcoming earnings on 10 Feb 2026
Upcoming earnings on 11 Nov 2025
EPS estimate is -$0.89.
Earnings released on 7 Aug 2025
EPS came in at -$0.95 falling short of the estimated -$0.83 by -14.46%.
Earnings released on 22 May 2025
EPS came in at -$0.82 falling short of the estimated -$0.75 by -9.33%, while revenue for the quarter reached $1.47M .
Earnings released on 12 Feb 2025
EPS came in at -$0.79 falling short of the estimated -$0.70 by -12.86%.
Earnings released on 12 Nov 2024
EPS came in at -$0.68 surpassing the estimated -$0.75 by +9.33%.
Earnings released on 8 Aug 2024
EPS came in at -$0.78 surpassing the estimated -$0.88 by +11.36%.
Earnings released on 16 May 2024
EPS came in at -$0.82 surpassing the estimated -$0.86 by +4.65%, while revenue for the quarter reached $4.04M .
Earnings released on 8 Feb 2024
EPS came in at -$0.77 surpassing the estimated -$0.94 by +18.09%.
Earnings released on 7 Nov 2023
EPS came in at -$0.90 falling short of the estimated -$0.80 by -12.50%.
Earnings released on 3 Aug 2023
EPS came in at -$0.75 surpassing the estimated -$0.85 by +11.76%.
Earnings released on 18 May 2023
EPS came in at -$0.74 falling short of the estimated -$0.66 by -12.12%.
Earnings released on 9 Feb 2023
EPS came in at -$0.69 surpassing the estimated -$0.77 by +10.39%.
Earnings released on 3 Nov 2022
EPS came in at -$0.79 falling short of the estimated -$0.78 by -1.28%.
Earnings released on 4 Aug 2022
EPS came in at -$0.78 falling short of the estimated -$0.63 by -23.81%.
Earnings released on 19 May 2022
EPS came in at -$0.60 matching the estimated -$0.60.
Earnings released on 3 Feb 2022
EPS came in at -$0.57 surpassing the estimated -$0.58 by +1.72%.
Earnings released on 4 Nov 2021
EPS came in at -$0.56 falling short of the estimated -$0.55 by -1.82%.
Earnings released on 6 Aug 2021
EPS came in at -$0.53 falling short of the estimated -$0.45 by -17.78%.
Earnings released on 20 May 2021
EPS came in at -$0.41 matching the estimated -$0.41.
Earnings released on 4 Feb 2021
EPS came in at -$0.44 falling short of the estimated -$0.41 by -7.32%.
Earnings released on 5 Nov 2020
EPS came in at -$0.46 falling short of the estimated -$0.43 by -6.98%.
REPL Stock Performance
Access detailed REPL performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.